ENGLISH
|
JAPANESE
|
CONNECT WITH US:
Home
About
Contact
Log in
*
Home
Press release
Dec 01, 2022 20:09 JST
Source:
Eisai
Eisai to Present Preclinical and Clinical Research on Eribulin at the 2022 San Antonio Breast Cancer Symposium
TOKYO, Dec 01, 2022 - (JCN Newswire) - Eisai Co., Ltd. announced today that new study results on its in-house discovered and developed anticancer agent eribulin mesylate (HALAVEN, "eribulin") will be presented during the 2022 San Antonio Breast Cancer Symposium (SABCS), which is taking place virtually and in-person in San Antonio, Texas from December 6-10.
Eisai will present five eribulin-related abstracts, including a post hoc subgroup analysis from two pivotal Phase 3 studies (EMBRACE and Study 301), as well as:
- Real world use of eribulin following treatment with a P13K inhibitor, mostly in people with Hormone Receptor (HR)-positive/HER2-negative metastatic breast cancer.
- Preclinical data exploring a liposomal formulation of eribulin, in a Phase 1 expansion cohort for breast cancer, versus eribulin at the same dose, in patient-derived breast cancer xenografts.
"We continue to relentlessly pursue research that provides useful insights for people living with breast cancer," said Dr. Takashi Owa, Chief Scientific Officer, Senior Vice President, Eisai Co., Ltd. "A big part of this commitment is the ongoing sharing of our preclinical and clinical data with eribulin."
This release discusses investigational compounds and investigational uses for FDA-approved products. It is not intended to convey conclusions about efficacy and safety. There is no guarantee that any investigational compounds or investigational uses of FDA-approved products will successfully complete clinical development or gain FDA approval.
For more information, visit www.eisai.com/news/2022/news202286.html.
Source: Eisai
Sectors: BioTech
Copyright ©2025 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.
Latest Release
MHI and Nippon Shokubai to Develop Ammonia Cracking System for NEDO's "Development of Technologies for Building a Competitive Hydrogen Supply Chain" Project
Oct 30, 2025 23:14 JST
NEC and e& Sign MoU to Drive Joint Sustainability Initiatives
Oct 30, 2025 22:46 JST
MHI Thermal Systems Launches Two New Models of Air-to-Water Heat Pumps Using Natural Refrigerant R290 for European Market
Oct 30, 2025 22:19 JST
Hitachi Energy and Blackstone Energy Transition Partners enter strategic partnership to create leading energy service provider in North America
Oct 30, 2025 21:40 JST
MHI-MS to Conduct Demonstration Testing of Vehicle Transport Robots at Nakagusuku Port in Okinawa
Oct 30, 2025 17:58 JST
DENSO Hosted a Press Briefing at JAPAN MOBILITY SHOW 2025
Oct 30, 2025 17:29 JST
Eisai and Merck & Co., Inc., Rahway, NJ, USA Provide Update on Phase 3 LEAP012 Trial in Unresectable, Non-Metastatic Hepatocellular Carcinoma
Oct 30, 2025 14:43 JST
Mazda Presents World Premiere of Two Vision Models at Japan Mobility Show 2025
Oct 30, 2025 14:33 JST
Mazda Rolls Out New Version of Brand Symbol from Japan Mobility Show 2025
Oct 30, 2025 14:26 JST
NEC and the Cambodian Mine Action Center Successfully Predict Landmine-Contaminated Areas in Cambodia Using AI
Oct 30, 2025 14:18 JST
Overview of Honda CEO Speech at the Japan Mobility Show 2025
Oct 30, 2025 14:00 JST
Honda Presents World Premiere of the Prototype of Honda 0 a, new SUV Model for Honda 0 Series at Japan Mobility Show 2025
Oct 30, 2025 11:55 JST
Honda Presents World Premiere of Super-ONE Prototype Compact EV at Japan Mobility Show 2025
Oct 30, 2025 11:50 JST
Mitsubishi Motors Debuts Mitsubishi Elevance Concept and Adventure-Inspiring Lineup at Japan Mobility Show 2025
Oct 30, 2025 11:39 JST
Fujitsu and PwC Japan partner on economic security measures for sovereign cloud solution
Oct 30, 2025 11:22 JST
Hitachi Rail becomes world's first transportation firm to adopt new NVIDIA IGX Thor solution for real-time AI
Oct 30, 2025 11:00 JST
Olympus Introduces NBI+TXI(TM) Observation Mode to the EVIS X1(TM) Endoscopy System CV-1500 Video System Center
Oct 29, 2025 11:00 JST
Gannon & Scott has signed a definitive agreement to join Metalor Technologies
Oct 29, 2025 04:00 JST
Merck & Co., Inc. and Eisai Announce WELIREG(R) (belzutifan) Plus LENVIMA(R) (lenvatinib) Met Primary Endpoint of Progression-Free Survival (PFS) in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma
Oct 29, 2025 00:30 JST
Mitsubishi Heavy Industries Machinery Systems to Exhibit at Japan Mobility Show 2025
Oct 29, 2025 00:00 JST
More Latest Release >>
Related Release
Eisai and Merck & Co., Inc., Rahway, NJ, USA Provide Update on Phase 3 LEAP012 Trial in Unresectable, Non-Metastatic Hepatocellular Carcinoma
10/30/2025 2:43:00 PM JST
Merck & Co., Inc. and Eisai Announce WELIREG(R) (belzutifan) Plus LENVIMA(R) (lenvatinib) Met Primary Endpoint of Progression-Free Survival (PFS) in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma
10/29/2025 12:30:00 AM JST
Health Canada Grants Authorization for "LEQEMBI(R)" (lecanemab) for the Treatment of Early Alzheimer's Disease
10/27/2025 2:23:00 PM JST
LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) Subcutaneous Autoinjector Named to TIME's "Best Inventions of 2025"
10/14/2025 5:54:00 PM JST
Eisai and Biogen Announce U.S. Availability of LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) Subcutaneous Injection Maintenance Dose for Treatment of Early Alzheimer's Disease
10/8/2025 12:03:00 PM JST
Eisai Highlights Breadth of Oncology Research at ESMO 2025
10/3/2025 6:01:00 PM JST
"LEQEMBI(R)" (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease Approved in China
9/29/2025 10:33:00 AM JST
LEQEMBI(R) (Lecanemab) Approved for the Treatment of Alzheimer's Disease in Australia
9/24/2025 7:04:00 PM JST
Anti-MTBR (microtubule binding region) Tau Antibody Etalanetug Granted FDA Fast Track Designation
9/17/2025 6:20:00 PM JST
"New Answers to Dementia" Eisai Releases Concept Movie and New Content on Campaign Website for Dementia Month
9/12/2025 1:20:00 PM JST
More Press release >>